Axon Enterprise - AXON Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXON shares.
View AXON analyst ratings or view top-rated stocks.

9 brokerages have issued twelve-month price objectives for Axon Enterprise's stock. Their AXON share price forecasts range from $120.00 to $232.00. On average, they expect the company's share price to reach $164.22 in the next twelve months. This suggests a possible upside of 43.4% from the stock's current price.
View analysts price targets for AXON or view top-rated stocks among Wall Street analysts.

Axon Enterprise's stock was trading at $157.00 at the beginning of the year. Since then, AXON shares have decreased by 27.0% and is now trading at $114.56.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our AXON earnings forecast.

Axon Enterprise, Inc. (NASDAQ:AXON) released its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.62. The biotechnology company had revenue of $285.61 million for the quarter, compared to analysts' expectations of $258.96 million. Axon Enterprise had a net margin of 14.20% and a trailing twelve-month return on equity of 12.57%. The company's quarterly revenue was up 30.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.72) earnings per share.

Axon Enterprise issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.07 billion-$1.12 billion, compared to the consensus revenue estimate of $1.27 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

(AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Shares of AXON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXON stock can currently be purchased for approximately $114.56.

Axon Enterprise (NASDAQ:AXON) has a market capitalization of $8.14 billion and generates $863.38 million in revenue each year. The biotechnology company earns $-60,020,000.00 in net income (profit) each year or $1.95 on an earnings per share basis.

The company employs 2,992 workers across the globe.

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The official website for the company is www.axovant.com. The biotechnology company can be reached via phone at (480) 991-0797, via email at ir@axon.com, or via fax at 480-991-0791.